--- title: "CICC Remains a Buy on Everest Medicines Ltd. (1952)" type: "News" locale: "en" url: "https://longbridge.com/en/news/281703087.md" description: "In a report released yesterday, from CICC maintained a Buy rating on Everest Medicines Ltd., with a price target of HK$55.00.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Everest Medicines Ltd. is a Moderate Buy with an average price target of HK$55.00." datetime: "2026-04-05T05:25:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281703087.md) - [en](https://longbridge.com/en/news/281703087.md) - [zh-HK](https://longbridge.com/zh-HK/news/281703087.md) --- # CICC Remains a Buy on Everest Medicines Ltd. (1952) In a report released yesterday, from CICC maintained a Buy rating on Everest Medicines Ltd., with a price target of HK$55.00. ### End of Quarter Sale - 50% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Everest Medicines Ltd. is a Moderate Buy with an average price target of HK$55.00. ### Related Stocks - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159567.CN](https://longbridge.com/en/quote/159567.CN.md) - [01952.HK](https://longbridge.com/en/quote/01952.HK.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) ## Related News & Research - [11:14 ETRibo y Boehringer Ingelheim siguen avanzando en su programa de siRNA](https://longbridge.com/en/news/285402650.md) - [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md) - [07:55 ETSupport Egg Quality and Ovulation with Nature's Bounty® New Fertility Supplement*](https://longbridge.com/en/news/285200796.md) - [Kepler Capital Sticks to Its Buy Rating for Affluent Medical SA (0JZ)](https://longbridge.com/en/news/285294988.md)